Merck Gets Conditional European Commission Approval for Ebola Vaccine
November 11 2019 - 3:58PM
Dow Jones News
By Micah Maidenberg
Merck & Co. (MRK) said European regulators granted the
company conditional approval to start marketing a vaccine that
targets the Ebola virus.
The pharmaceutical company now has permission from the European
Commission to begin producing doses of the vaccine, called Ervebo,
in Germany.
The drug is expected to be available starting in the third
quarter next year, Merck said Monday. The commission's decisions
allows Merck to market the drug in the in the European Union, as
well as in Iceland, Liechtenstein and Norway. Ervebo is for adults
ages 18 and older.
The U.S. Food and Drug Administration is currently has the
vaccine under priority review, with a target action date of March
14, 2020, Merck said.
Merck is also working with the World Health Organization, the
U.S. government and others to provide an investigational vaccine
for Ebola called V920. That drug is being used in to fight an Ebola
outbreak in the Democratic Republic of Congo.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
November 11, 2019 15:43 ET (20:43 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024